Shanghai Henlius (2696) Announces 2025 Fourth EGM and Seeks Approval for Sinopharm Distribution Framework Agreement

Bulletin Express

Dec 03

Shanghai Henlius Biotech, Inc. (the “Company,” Stock Code: 2696) has released a proxy form for its 2025 fourth extraordinary general meeting (EGM), scheduled for 31 December 2025 at 9:00 a.m. The EGM will take place in the Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, People’s Republic of China.

Key business on the agenda includes consideration and potential approval of a Distribution Framework Agreement dated 3 December 2025 between the Company and Sinopharm Group Co. Ltd.* (國藥控股股份有限公司). The meeting will also review the corresponding annual caps for the proposed arrangement. Shareholders or their proxies who plan to attend must complete and submit the proxy form within the required deadline outlined in the announcement.

According to the proxy instruction, shareholders can appoint one or more representatives to vote on their behalf. The form specifies the necessary procedures for lodging such appointments and emphasizes the requirement to adhere to the designated timeline. If the proposal is passed, any Director of the Company will be authorized to undertake actions needed to implement the newly approved agreement frameworks and related transactions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1182071381"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182071381\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182071381?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182071381","market":"hk","top_or_hot":-1,"title":"Shanghai Henlius (2696) Announces 2025 Fourth EGM and Seeks Approval for Sinopharm Distribution Framework Agreement","media":"Bulletin Express","content":"<p>Shanghai Henlius Biotech, Inc. (the “Company,” Stock Code: 2696) has released a proxy form for its 2025 fourth extraordinary general meeting (EGM), scheduled for 31 December 2025 at 9:00 a.m. The EGM will take place in the Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, People’s Republic of China.</p>\n<p>Key business on the agenda includes consideration and potential approval of a Distribution Framework Agreement dated 3 December 2025 between the Company and Sinopharm Group Co. Ltd.* (國藥控股股份有限公司). The meeting will also review the corresponding annual caps for the proposed arrangement. Shareholders or their proxies who plan to attend must complete and submit the proxy form within the required deadline outlined in the announcement.</p>\n<p>According to the proxy instruction, shareholders can appoint one or more representatives to vote on their behalf. The form specifies the necessary procedures for lodging such appointments and emphasizes the requirement to adhere to the designated timeline. If the proposal is passed, any Director of the Company will be authorized to undertake actions needed to implement the newly approved agreement frameworks and related transactions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Henlius (2696) Announces 2025 Fourth EGM and Seeks Approval for Sinopharm Distribution Framework Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Henlius (2696) Announces 2025 Fourth EGM and Seeks Approval for Sinopharm Distribution Framework Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-03 22:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Henlius Biotech, Inc. (the “Company,” Stock Code: 2696) has released a proxy form for its 2025 fourth extraordinary general meeting (EGM), scheduled for 31 December 2025 at 9:00 a.m. The EGM will take place in the Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, People’s Republic of China.</p>\n<p>Key business on the agenda includes consideration and potential approval of a Distribution Framework Agreement dated 3 December 2025 between the Company and Sinopharm Group Co. Ltd.* (國藥控股股份有限公司). The meeting will also review the corresponding annual caps for the proposed arrangement. Shareholders or their proxies who plan to attend must complete and submit the proxy form within the required deadline outlined in the announcement.</p>\n<p>According to the proxy instruction, shareholders can appoint one or more representatives to vote on their behalf. The form specifies the necessary procedures for lodging such appointments and emphasizes the requirement to adhere to the designated timeline. If the proposal is passed, any Director of the Company will be authorized to undertake actions needed to implement the newly approved agreement frameworks and related transactions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"","article_id":"1182071381","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182071381","pubTimestamp":1764771900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Henlius Biotech, Inc. (the “Company,” Stock Code: 2696) has released a proxy form for its 2025 fourth extraordinary general meeting (EGM), scheduled for 31 December 2025 at 9:00 a.m. The EGM...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖"},"translate_title":"复宏汉霖(2696)公布2025年第四次临时股东大会寻求批准国药分销框架协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shanghai Henlius Biotech, Inc. (the “Company,” Stock Code: 2696) has released a proxy form for its 2025 fourth extraordinary general meeting (EGM), scheduled for 31 December 2025 at 9:00 a.m. The EGM will take place in the Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, People’s Republic of China.\nKey business on the agenda includes consideration and potential approval of a Distribution Framework Agreement dated 3 December 2025 between the Company and Sinopharm Group Co. Ltd.* (國藥控股股份有限公司). The meeting will also review the corresponding annual caps for the proposed arrangement. Shareholders or their proxies who plan to attend must complete and submit the proxy form within the required deadline outlined in the announcement.\nAccording to the proxy instruction, shareholders can appoint one or more representatives to vote on their behalf. The form specifies the necessary procedures for lodging such appointments and emphasizes the requirement to adhere to the designated timeline. If the proposal is passed, any Director of the Company will be authorized to undertake actions needed to implement the newly approved agreement frameworks and related transactions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}